Breakthrough Therapies for Skin Cancer

MedC Biopharma Corporation is a clinical-stage biopharmaceutical company focused on developing and commercializing a novel class of formulated phyto-cannabinoid therapeutics for the treatment of non-melanoma skin cancers.


CTCL stands for cutaneous T-cell lymphoma, a rare cancer of T-lymphocytes (a type of white blood cells) that involves the skin. There are several types of CTCL, but mycosis fungoides and Sézary syndrome are the most common. The global market for CTCL is estimated to reach $1.6 Billion by 2025 (Diligent Market Research, 2017).

Actinic Keratosis

Actinic keratosis (AK), also known as solar keratosis, is a pre-cancerous skin condition caused by too much exposure to the sun. According to Credence Research, the AK market is expected to reach $8,9 Billion by 2022. It is estimated that 58 million people in the US have AK and over 200 million world-wide.

Squamous & Basal Cell Carcinomas

According to Skin Cancer Foundation report, 2019, an estimate of 5.4 million squamous and basal cell skin cancers are diagnosed each year in US. Basal and squamous cell skin cancers are the most common types of skin cancer. They start in the top layer of skin and are often related to sun exposure.


©2020 MedCbiopharma. All Rights Reserved. Proudly created by wix_pro

229 Yonge Street #400
Toronto, ON M5B 1N9 Canada